PCSK9 Antikörper (AA 153-380)

Produktnummer ABIN7164832

Produktdetails anti-PCSK9 Antikörper

Target: PCSK9 (Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9))

Bindungsspezifität: AA 153-380

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser PCSK9 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Immunofluorescence (IF)

Kreuzreaktivität: Human

Aufreinigung: >95%, Protein G purified

Immunogen: Recombinant Human Proprotein convertase subtilisin/kexin type 9 protein (153-380AA)

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Recommended dilution: WB:1:1000-1:5000, IHC:1:500-1:1000, IF:1:50-1:200,

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Details zu PCSK9

Target: PCSK9 (Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9))

Andere Bezeichnung: PCSK9 (PCSK9 Produkte)

Synonyme: FH3 antikoerper, HCHOLA3 antikoerper, LDLCQ1 antikoerper, NARC-1 antikoerper, NARC1 antikoerper, PC9 antikoerper, AI415265 antikoerper, AI747682 antikoerper, Narc1 antikoerper, proprotein convertase subtilisin/kexin type 9 antikoerper, proprotein convertase subtilisin/kexin type 9 L homeolog antikoerper, PCSK9 antikoerper, pcsk9.L antikoerper, pcsk9 antikoerper, Pcsk9 antikoerper

Hintergrund:

Background: Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments (PubMed:18039658). Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation (PubMed:18799458, PubMed:17461796, PubMed:18197702, PubMed:22074827). Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway (PubMed:18660751). Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.

Aliases: Convertase subtilisin/kexin type 9 preproprotein antibody, FH3 antibody, HCHOLA3 antibody, Hypercholesterolemia autosomal dominant 3 antibody, LDLCQ1 antibody, NARC 1 antibody, NARC-1 antibody, NARC1 antibody, Neural apoptosis regulated convertase 1 antibody, Neural apoptosis-regulated convertase 1 antibody, PC 9 antibody, PC9 antibody, PCSK 9 antibody, PCSK9 antibody, PCSK9_HUMAN antibody, Proprotein convertase 9 antibody, Proprotein convertase PC9 antibody, Proprotein convertase subtilisin/kexin type 9 antibody, PSEC0052 antibody, Subtilisin/kexin like protease PC9 antibody, Subtilisin/kexin-like protease PC9 antibody

UniProt: Q8NBP7